HERITAGE PHARMA
GenericsHERITAGE PHARMA is a generic drug manufacturer focused on Cardiovascular, Neurology, Immunology.
HERITAGE PHARMA's Key Drugs
HERITAGE PHARMA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
HERITAGE PHARMA's Recent FDA Approvals
New NDA/BLA approvals for HERITAGE PHARMA over the last two years — novel drugs only, excluding generics and label supplements.
HERITAGE PHARMA's Therapeutic Areas
HERITAGE PHARMA's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
HERITAGE PHARMA's Top Competitors
HERITAGE PHARMA's closest competitors by therapeutic-area and drug-target overlap include BAUSCH, Novartis, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
HERITAGE PHARMA Pipeline Snapshot
Active clinical trials for HERITAGE PHARMA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1972-08-24
- Latest
- 2026-04-02
- Applications
- 53